Cargando…

Morphological screens using aged primary adult neuronal, microglial, and astrocytic cultures to find novel neurotherapeutics

The average age of a patient with neurotraumatic injuries or neurodegenerative diseases has been increasing worldwide. The preclinical live animal models used for neurotrauma and neurodegenerative diseases are typically young adults, failing to represent the age of humans in the clinic. This dichoto...

Descripción completa

Detalles Bibliográficos
Autor principal: Sefiani, Arthur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484707/
https://www.ncbi.nlm.nih.gov/pubmed/37692551
http://dx.doi.org/10.3389/fncel.2023.1253192
_version_ 1785102640725622784
author Sefiani, Arthur
author_facet Sefiani, Arthur
author_sort Sefiani, Arthur
collection PubMed
description The average age of a patient with neurotraumatic injuries or neurodegenerative diseases has been increasing worldwide. The preclinical live animal models used for neurotrauma and neurodegenerative diseases are typically young adults, failing to represent the age of humans in the clinic. This dichotomy in age between human populations and animal models is likely to impede the understanding of the pathological mechanisms of most neurological disorders and the translation of their respective promising therapies. This lack of cohesion between animal models and patients in the clinic begins prior to in vivo testing, it starts during the in vitro drug screening phase. Conventional screening methods typically involve the use of stem cell derived neural cells, with some researchers using embryonic derived neural cells instead. These cells lack the fundamental characteristics present in aged neural cells, such as age-induced changes in process length and branching in microglia and how astrocytes respond to various insults. Various technologies and techniques have been developed recently that can help researchers use age-appropriate neural cells for their drug discovery endeavors. The use of age-appropriate neural cells during screening phases is hypothesized to significantly increase the translation rate of the hits to the geriatric patients suffering from neurotraumatic and neurodegenerative diseases.
format Online
Article
Text
id pubmed-10484707
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104847072023-09-08 Morphological screens using aged primary adult neuronal, microglial, and astrocytic cultures to find novel neurotherapeutics Sefiani, Arthur Front Cell Neurosci Neuroscience The average age of a patient with neurotraumatic injuries or neurodegenerative diseases has been increasing worldwide. The preclinical live animal models used for neurotrauma and neurodegenerative diseases are typically young adults, failing to represent the age of humans in the clinic. This dichotomy in age between human populations and animal models is likely to impede the understanding of the pathological mechanisms of most neurological disorders and the translation of their respective promising therapies. This lack of cohesion between animal models and patients in the clinic begins prior to in vivo testing, it starts during the in vitro drug screening phase. Conventional screening methods typically involve the use of stem cell derived neural cells, with some researchers using embryonic derived neural cells instead. These cells lack the fundamental characteristics present in aged neural cells, such as age-induced changes in process length and branching in microglia and how astrocytes respond to various insults. Various technologies and techniques have been developed recently that can help researchers use age-appropriate neural cells for their drug discovery endeavors. The use of age-appropriate neural cells during screening phases is hypothesized to significantly increase the translation rate of the hits to the geriatric patients suffering from neurotraumatic and neurodegenerative diseases. Frontiers Media S.A. 2023-08-23 /pmc/articles/PMC10484707/ /pubmed/37692551 http://dx.doi.org/10.3389/fncel.2023.1253192 Text en Copyright © 2023 Sefiani. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Sefiani, Arthur
Morphological screens using aged primary adult neuronal, microglial, and astrocytic cultures to find novel neurotherapeutics
title Morphological screens using aged primary adult neuronal, microglial, and astrocytic cultures to find novel neurotherapeutics
title_full Morphological screens using aged primary adult neuronal, microglial, and astrocytic cultures to find novel neurotherapeutics
title_fullStr Morphological screens using aged primary adult neuronal, microglial, and astrocytic cultures to find novel neurotherapeutics
title_full_unstemmed Morphological screens using aged primary adult neuronal, microglial, and astrocytic cultures to find novel neurotherapeutics
title_short Morphological screens using aged primary adult neuronal, microglial, and astrocytic cultures to find novel neurotherapeutics
title_sort morphological screens using aged primary adult neuronal, microglial, and astrocytic cultures to find novel neurotherapeutics
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484707/
https://www.ncbi.nlm.nih.gov/pubmed/37692551
http://dx.doi.org/10.3389/fncel.2023.1253192
work_keys_str_mv AT sefianiarthur morphologicalscreensusingagedprimaryadultneuronalmicroglialandastrocyticculturestofindnovelneurotherapeutics